Comparative Pharmacology
Head-to-head clinical analysis: TRANDOLAPRIL versus UNIVASC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRANDOLAPRIL versus UNIVASC.
TRANDOLAPRIL vs UNIVASC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trandolapril is a prodrug that is hydrolyzed to its active metabolite trandolaprilat, which inhibits angiotensin-converting enzyme (ACE), blocking the conversion of angiotensin I to angiotensin II. This reduces vasoconstriction, aldosterone secretion, and sodium reabsorption, leading to decreased blood pressure and preload/afterload reduction.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
1–2 mg orally once daily; maximum 4 mg once daily.
Initial: 7.5 mg orally once daily; titrate to 15-30 mg once daily. Maximum: 60 mg/day.
None Documented
None Documented
Clinical Note
moderateTrandolapril + Etacrynic acid
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Etacrynic acid."
Clinical Note
moderateTrandolapril + Furosemide
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Furosemide."
Clinical Note
moderateTrandolapril + Bumetanide
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Bumetanide."
Clinical Note
moderateTrandolapril: 6 hours; Trandolaprilat: 24 hours (terminal); effective half-life for ACE inhibition: ~24 hours allowing once-daily dosing
The terminal elimination half-life of moexiprilat, the active metabolite, is approximately 9.8 hours in patients with normal renal function. This supports once-daily dosing, though the antihypertensive effect may persist beyond 24 hours with continued therapy.
Renal: 33% (as trandolaprilat); Fecal: 66% (as trandolapril and trandolaprilat); Biliary: minimal
Univasc (moexipril) is primarily eliminated via renal excretion (approximately 50% of absorbed dose as unchanged drug and metabolites) and fecal excretion (about 50%).
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor
Trandolapril + Benzydamine
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Benzydamine."